MARKET

EVOK

EVOK

Evoke Pharma Inc
NASDAQ
1.900
-0.078
-3.94%
Opening 12:30 09/29 EDT
OPEN
2.000
PREV CLOSE
1.978
HIGH
2.300
LOW
1.880
VOLUME
14.03K
TURNOVER
25.86K
52 WEEK HIGH
17.40
52 WEEK LOW
1.810
MARKET CAP
6.35M
P/E (TTM)
-0.6681
1D
5D
1M
3M
1Y
5Y
Evoke to get US patent for nasal spray Gimoti
Evoke Pharma (NASDAQ:EVOK) <a href="https://seekingalpha.com/p...
Seekingalpha · 09/20 15:35
Evoke Pharma Receives Notice Of Allowance From USPTO For A Patent Related To GIMOTI
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
Benzinga · 09/20 12:35
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- E...
GlobeNewswire · 09/14 12:30
Evoke, Eversana to launch telehealth solution for Gimoti
Evoke Pharma (NASDAQ:EVOK) and Eversana are <a href="https://s...
Seekingalpha · 08/16 13:32
BRIEF-Evoke Pharma and Eversana expand patient access to Gimoti® with new telehealth solution
BRIEF-Evoke Pharma and Eversana expand patient access to Gimoti® with new telehealth solution
Reuters · 08/16 12:33
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealthSOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company...
GlobeNewswire · 08/16 12:30
Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Evoke Pharma press release (NASDAQ:<a href="...
Seekingalpha · 08/10 20:23
BRIEF-Evoke Pharma Reports Second Quarter 2022 Financial Results
BRIEF-Evoke Pharma Reports Second Quarter 2022 Financial Results
Reuters · 08/10 20:19
More
About EVOK
Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company that owns and operates in the development and commercialization of pharmaceutical products. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.